Publications by authors named "David Heigener"

Claim this Profile
F
Feasibility of evaluating AI-enabled digital symptom monitoring in metastatic patients with NSCLC receiving pembrolizumab therapy: A German single-arm observational pilot study.
Melissa L Santorelli, Oliver Schmalz, Mathias Hoiczyk, David Heigener, Clemens Schulte

Digit Health· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Palliative aspects in pulmonary oncology].
David Heigener, Sandra Delis

Pneumologie· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients.
Mustafa Abdo, Yassine Belloum, David Heigener, Lutz Welker, Sönke von Weihe

Mol Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?
David F Heigener, Martin Reck

Drugs· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint blockade in small cell lung cancer.
Rebecca Y Tay, David Heigener, Martin Reck, Raffaele Califano

Lung Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer.
David F Heigener, Keith M Kerr, Gavin M Laing, Tony S K Mok, Fedor V Moiseyenko

Clin Cancer Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib.
David F Heigener, Martin Reck

Recent Results Cancer Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Same….
David F Heigener, Martin Reck

J Thorac Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.
David F Heigener, Martin Reck

J Thorac Dis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung cancer in 2017: Giant steps and stumbling blocks.
David F Heigener, Martin Reck

Nat Rev Clin Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
Maya Gottfried, Jaafar Bennouna, Igor Bondarenko, Jean-Yves Douillard, David F Heigener

Target Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-Line Treatment Selection in Patients With Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians.
Nicolas Girard, Jesus Corral, Diego Cortinovis, David F Heigener

Clin Lung Cancer· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?
David F Heigener, Martin Reck

J Thorac Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Chemotherapy in the Elderly with Non-Small Cell Lung Cancer: A Non-Interventional, Prospective, Multicentric Observational Study].
David Felix Heigener, Gert Hoeffken, Dieter Wuerflein, Matthias Feurer, Achim Rittmeyer

Dtsch Med Wochenschr· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurement of quality of life in second-line patients with advanced NSCLC without targetable mutations: a review.
David Heigener, Thomas Küchler

Lung Cancer Manag· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy for small-cell lung cancer: emerging evidence.
Martin Reck, David Heigener, Niels Reinmuth

Future Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy: the third wave in lung cancer treatment.
David Felix Heigener, Martin Reck

Lancet Respir Med· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
David F Heigener, Christian Schumann, Martin Sebastian, Parvis Sadjadian, Ingo Stehle

Oncologist· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial.
David F Heigener, José Rodrigues Pereira, Enriqueta Felip, Juraj Mazal, Lyudmila Manzyuk

Target Oncol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting of MEK in lung cancer therapeutics.
David F Heigener, David R Gandara, Martin Reck

Lancet Respir Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel angiogenesis inhibitors in nonsmall cell lung cancer.
Niels Reinmuth, David Heigener, Martin Reck

Curr Opin Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Non-small cell lung cancer: news from immunotherapy].
Niels Reinmuth, David F Heigener, Martin Reck

Dtsch Med Wochenschr· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany.
Dieter Hörsch, Kurt W Schmid, Martin Anlauf, Kaid Darwiche, Tim Denecke, David F Heigener

Oncol Res Treat· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer.
David Heigener, Martin Reck

Expert Rev Anticancer Ther· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.
Martin Reck, David Heigener, Niels Reinmuth

Expert Rev Clin Pharmacol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis